The returning client is a midsize US pharma company developing inhaled therapies. The customer has decided to test another one of its inhaled drug formulation candidates using ISAB's preclinical in vitro testing module DissolvIt, following successful results from its previous IRS / DissolvIt project. The new project is worth 98,000 Euro.

According to feedback received from the client, DissolvIt is the first in vitro dissolution method they have found that generated data of such quality that it enabled them to make reliable `go/no-go' decisions on which formulations to proceed with in the early stages of drug development. Predicting failure at the preclinical stage can produce enormous savings in a market where, according to a 2020 study, the average cost of getting a new drug onto the market through all stages of drug development is 1.3 BUSD [1].

The discriminative power of ISAB's DissolvIt technology in comparing small differences between drug formulations aimed for administration via inhalation, is currently being evaluated in an FDA BAA (Broad Agency Announcement) contract research project being carried out at ISAB's facilities in Sweden.

ISAB CEO Manoush Masarrat: "Our technology enables clients to get it right first time when it comes to drug development - making secure decisions on which formulations to invest further in, which to eliminate, and how best to move ahead safely in an exceptionally high-risk and costly field. This new order from a returning customer, once again reconfirms the unique predictive power of our technology - and we are delighted to welcome back this client of ours."

Discover DissolvIt[®]

Read ISAB's publications on DissolvIt[®]here. (https://www.inhalation.se/publications/)

Discover DissolvIt's in vitro capabilities here. (https://www.inhalation.se/inhalation-research-services/dissolvit-in-vitro-dissolution/)

Explore Inhalation Research Services here (https://www.inhalation.se/inhalation-research-services/)

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054832/